Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 22 of 22 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	Sitravatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sitravatinib (MGCD516) inhibited proliferation of transformed hematologic cells expressing FLT3-ITD with FLT3 Y842C in culture, and resulted in an increased median survival compared to the vehicle-treated group (P<0.001) in a cell line xenograft model (PMID: 36691065).	36691065
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	resistant	Quizartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FLT3-ITD and FLT3 Y842C were resistant to treatment with Vanflyta (quizartinib) in culture and in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 Y842C and improved survival in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	Foretinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 Y842C and improved survival in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 Y842C	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668).	27158668
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Sutent (sunitinib) in culture (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Nexavar (sorafenib) in culture (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	AGL2043	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to AGL2043 in culture (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Lestaurtinib (CEP-701) in culture (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Rydapt (midostaurin) in culture (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited Flt3 autophosphorylation and cell proliferation of transformed 32Dcl3 murine myeloid cells expressing a human FLT3-ITD/Y842C compound mutation (PMID: 29187377).	29187377
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	resistant	KW-2449	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells co-expressing FLT3 ITD and FLT3 Y842C were resistant to treatment with KW-2449 in culture (PMID: 22858906).	22858906
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells co-expressing FLT3 ITD and FLT3 Y842C were resistant to treatment with Vanflyta (quizartinib) in culture (PMID: 22858906).	22858906
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	LT-171-861	Preclinical - Cell culture	Actionable	In a preclinical study, LT-171-861 inhibited cell viability and decreased FLT3 phosphorylation in transformed cells expressing a FLT3-ITD mutation and FLT3 Y842C in culture (PMID: 33391463).	33391463
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101 treatment inhibited growth of acute myeloid leukemia cells harboring FLT3-ITD and FLT3 Y842C in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 ITD with FLT3 Y842C in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in acute myeloid leukemia cells harboring FLT3 ITD with FLT3 Y842C in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring FLT3 ITD with FLT3 Y842C were resistant to Vanflyta (quizartinib) in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited viability in an acute myeloid leukemia cell line harboring FLT3 ITD and expressing FLT3 Y842C in culture (PMID: 37992684).	37992684
FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	Ningetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 Y842C in culture (PMID: 38978049).	38978049
FLT3 exon 14 ins FLT3 Y842C	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).	25847190
FLT3 exon 14 ins FLT3 Y842C	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).	26822154

Showing 1 to 22 of 22 entries

Filter rows:

Profile Name	FLT3 exon 14 ins FLT3 Y842C
Gene Variant Detail	FLT3 exon 14 ins (gain of function - predicted) FLT3 Y842C (gain of function)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting